Parecoxib

MUSCULO-SKELETAL SYSTEM

Key facts

Parecoxib is a drug catalogued in DrugCentral. It was first approved by the EMA in 2002. DrugCentral lists 3 molecular targets, including PTGS2, NR4A2 and PTGS1. Recorded indications include Acute postoperative pain.

• Molecular targets: PTGS2, NR4A2 and PTGS1 (3 listed in DrugCentral).
• Indications: Acute postoperative pain.
• ATC code: M01AH04 (Coxibs).
• Molecular formula: C19H18N2O4S; molecular weight 370.42 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Acute postoperative pain

Mechanism & targets

Molecular targets (3)

Target	Gene	Action	Activity
Prostaglandin G/H synthase 2	PTGS2	inhibitor	IC50 8.30
Nuclear receptor subfamily 4 group A member 2	NR4A2	unknown	IC50 4.87
Prostaglandin G/H synthase 1	PTGS1	inhibitor	IC50 3.85

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2002-03-22	EMA	—	—

ATC classification

ATC code	Therapeutic hierarchy
M01AH04	MUSCULO-SKELETAL SYSTEM › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS › Coxibs

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Negative pressure pulmonary oedema	127.2
Anaphylactic reaction	77.7
Neuromuscular block prolonged	70.8
Oxygen saturation decreased	58.4
Tachypnoea	57.9

Chemical structure

• Molecular formula: C₁₉H₁₈N₂O₄S
• Molecular weight: 370.42 g/mol
• CAS number: 198470-84-7
• InChIKey: TZRHLKRLEZJVIJ-UHFFFAOYSA-N
• PubChem CID: 119828

CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C1=C(C)ON=C1C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Parecoxib used for?

DrugCentral lists the following indications for Parecoxib: Acute postoperative pain.

How does Parecoxib work?

Its molecular targets in DrugCentral include PTGS2 (inhibitor), NR4A2 and PTGS1 (inhibitor).

When was Parecoxib first approved?

Parecoxib was first approved by the EMA in 2002.

What is the chemical formula of Parecoxib?

Parecoxib has the molecular formula C19H18N2O4S and a molecular weight of 370.42 g/mol.

Sources

• DrugCentral drug card 2063 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1206690 — compound record and bioactivity
• PubChem CID 119828 — chemical identifiers
• DrugBank DB08439 — drug record
• FDA UNII 9TUW81Y3CE — substance identity
• UniProt P35354 (PTGS2) — target protein
• UniProt P43354 (NR4A2) — target protein
• UniProt P23219 (PTGS1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.